Selective targeting of toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma

International Journal of Cancer

Volumn 135, Issue 12, 2014, Pages 2834-2846

  Voo, Kui Shin ^a   Foglietta, Myriam ^a   Percivalle, Elena ^a   Chu, Fuliang ^a   Nattamai, Durga ^a   Harline, Megan ^a   Lee, Seung Tae ^a   Bover, Laura ^a   Lin, Heather Y ^a   Baladandayuthapani, Veerabhadran ^a   Delgado, David ^a   Luong, Amber ^b   Davis, R Eric ^a   Kwak, Larry W ^a   Liu, Yong Jun ^a   Neelapu, Sattva S ^a,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c Unit 903   (United States)

Author keywords

Immunotherapy; Lymphoma; OX40; Regulatory T cells; Toll like receptors

Indexed keywords

ANTINEOPLASTIC AGENT; CD134 ANTIGEN; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IL10 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; LIGAND; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TNFRSF4 PROTEIN, HUMAN; TOLL LIKE RECEPTOR;

ADULT; AGED; CELL SEPARATION; CYTOLOGY; DISEASE FREE SURVIVAL; DRUG EFFECTS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; IMMUNOTHERAPY; LYMPHOMA, FOLLICULAR; MALE; METABOLISM; MIDDLE AGED; PROCEDURES; REGULATORY T LYMPHOCYTE; REMISSION; TREATMENT OUTCOME; TUMOR CELL LINE; YOUNG ADULT;

ADULT; AGED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SEPARATION; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INTERLEUKIN-10; LIGANDS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, OX40; REMISSION INDUCTION; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908675997     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28937     Document Type: Article

References (52)

1. A clinical evaluation of the International Lymphoma Study Group classification of non- Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89: 3909-18.
2. BendandiM CDGocke CBKobrin alet Complete molecular remissions induced by patientspecific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma Nat Med 1999 5 1171-7
3. Neelapu SS, Baskar S, Gause BL, et al. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin Cancer Res 2004;10:8309-17.
4. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for Bcell lymphoma: clinical and immune responses in35 patients. Blood 2002;99:1517-26.
5. Park HJ, Neelapu SS. Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials. Br J Haematol 2008;142: 179-91.
6. Schuster SJ, Neelapu SS, Gause BL, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011;29: 2787-94.
7. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6: 295-307.
8. Yang ZZ, Novak AJ, Stenson MJ, et al. Intratumoral CD41CD251 regulatory T-cell-mediated suppression of infiltrating CD41 T cells in B-cell non-Hodgkin lymphoma. Blood 2006;107:3639- 46.
9. Hilchey SP, De A, Rimsza LM, et al. Follicular lymphoma intratumoral CD41CD251GITR1regulatory T cells potently suppress CD3/CD28- costimulated autologous and allogeneicCD81CD25- and CD41CD25- T cells. J Immunol 2007;178:4051-61.
10. Mittal S, Marshall NA, Duncan L, et al. Local and systemic induction of CD41CD251 regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008;111:5359-70.
11. Ai WZ, Hou JZ, Zeiser R, et al. Follicular lymphoma B cells induce the conversion of conventional CD41 T cells to T-regulatory cells. Int J Cancer 2009;124:239-44.
12. Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006;108:2957-64.
13. Alvaro T, Lejeune M, Salvado MT, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006;24:5350-7.
14. Farinha P, Al-Tourah A, Gill K, et al. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood 2010;115:289-95.
15. Houot R, Goldstein MJ, Kohrt HE, et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 2009;114:3431-8.
16. Houot R, Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 2009;113:3546-52.
17. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-95.
18. Wang RF, Miyahara Y, Wang HY. Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene 2008;27:181-9.
19. Crellin NK, Garcia RV, Hadisfar O, et al. Human CD41 T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD41CD251 T regulatory cells. J Immunol 2005;175:8051-9.
20. Chen Q, Davidson TS, Huter EN, et al. Engagement of TLR2 does not reverse the suppressor function of mouse regulatory T cells, but promotes their survival. J Immunol 2009;183:4458- 66.
21. Croft M, So T, Duan W, Soroosh P. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev 2009;229: 173-91.
22. Ito T, Wang YH, Duramad O, et al. OX40 ligand shuts down IL-10-producing regulatory T cells. Proc Natl Acad Sci USA 2006;103:13138-43.
23. So T, Croft M. Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD251Foxp31 T cells. J Immunol 2007;179:1427-30.
24. Hirschhorn-Cymerman D, Rizzuto GA, et al. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med 2009;206:1103-16.
25. Gough MJ, Ruby CE, Redmond WL, et al. OX40agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res 2008;68:5206-15.
26. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159-69.
27. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
28. Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014;15:69-77.
29. Lee ST, Liu S, Radvanyi L, et al. A novel strategy for rapid and efficient isolation of human tumorspecific CD4(1) and CD8(1) T-cell clones. J Immunol Methods 2008;331:13-26.
30. Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD41 T cells expressing the FoxP3 transcription factor. Immunity 2009;30:899-911.
31. Bourke E, Bosisio D, Golay J, et al. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 2003;102:956-63.
32. Patel M, Xu D, Kewin P, et al. TLR2 agonist ameliorates established allergic airway inflammation by promoting Th1 response and not via regulatory T cells. J Immunol 2005;174:7558-63.
33. Yamazaki S, Okada K, Maruyama A, et al. TLR2- dependent induction of IL-10 and Foxp31 CD25 1 CD41 regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PLoS One6:e18833.
34. Piconese S, Valzasina B, Colombo MP. OX40triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 2008; 205:825-39.
35. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD41CD251 regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-8.
36. Rawal S, Chu F, Zhang M, et al. Cross talk between follicular Th cells and tumor cells inhuman follicular lymphoma promotes immune evasion in the tumor microenvironment. J Immunol 2013;190:6681-93.
37. Navarrete MA, Heining-Mikesch K, Schuler F, et al. Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma. Blood 2011;117:1483-91.
38. Nyirenda MH, Sanvito L, Darlington PJ, et al. TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function. J Immunol 2011;187:2278-90.
39. Kubo T, Hatton RD, Oliver J, et al. Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells. J Immunol 2004; 173:7249-58.
40. Voo KS, Bover L, Harline ML, et al. Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function. J Immunol 2013;191:3641-50.
41. Taylor RC, Richmond P, Upham JW. Toll-like receptor 2 ligands inhibit TH2 responses to mite allergen. J Allergy Clin Immunol 2006;117:1148- 54.
42. Asai H, Iijima H, Matsunaga K, et al. Proteinbound polysaccharide K augments IL-2 production from murine mesenteric lymph node CD41 T cells by modulating T cell receptor signaling. Cancer Immunol Immunother 2008;57:1647-55.
43. Zhang Y, Luo F, Cai Y, et al. TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. J Immunol; 186:1963-9.
44. NapolitaniG RinaldiA BertoniF alet Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells Nat Immunol 2005 6 769-76
45. Zhu Q, Egelston C, Gagnon S, et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Investig 2010;120: 607-16.
46. Wahlin BE, Sundstrom C, Holte H, et al. T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab. Clin Cancer Res 2011;17:4136-44.
47. Christopoulos P, Pfeifer D, Bartholome K, et al.Definition and characterization of the systemic Tcell dysregulation in untreated indolent B-cell lymphoma and very early CLL.Blood;117:3836-46.
48. Koch MA, Tucker-Heard G, Perdue NR, et al.The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol 2009;10:595-602.
49. Zheng Y, Chaudhry A, Kas A, et al. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature 2009;458:351-6.
50. Chaudhry A, Rudra D, Treuting P, et al. CD41 regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 2009;326:986-91.
51. Chung Y, Tanaka S, Chu F, et al. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat Med 2011;17:983-8.
52. Ame-Thomas P, Le Priol J, Yssel H, et al. Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. Leukemia 2012;26:1053-63.